| Aug 1 |
Myriad Genetics completes sale of EndoPredict Business to Eurobio Scientific
|
| Aug 1 |
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
|
| Jul 31 |
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
|
| Jul 30 |
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
|
| Jul 18 |
INCY or MYGN: Which Is the Better Value Stock Right Now?
|
| Jul 17 |
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
|
| Jul 15 |
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
|
| Jul 11 |
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
|
| Jul 10 |
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
|
| Jul 9 |
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
|
